**Disc Medicine, Inc. Reports Financial Results and Operational Progress in Annual Filing**

Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on hematologic diseases, released its financial results and provided a business update in its recent 10-K filing. The company, which has not yet generated revenue from product sales, reported a net loss of $212.2 million for the year ended December 31, 2025, compared to a net loss of $109.4 million for the previous year. Research and development expenses increased significantly to $170.6 million in 2025 from $96.7 million in 2024, driven by the advancement of its clinical programs, particularly bitopertin, and increased personnel costs. Selling, general, and administrative expenses also rose to $65.4 million from $33.0 million, reflecting the company's expansion and development of commercialization capabilities.

The company's lead product candidate, bitopertin, for erythropoietic porphyrias (EPs), remains a key focus. While the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for accelerated approval, citing a lack of direct correlation between PPIX reduction and clinical benefit, Disc Medicine is planning a Type A meeting with the FDA to discuss the path forward. Topline data from the ongoing Phase 3 APOLLO trial, intended as a confirmatory study, is expected in the fourth quarter of 2026, with a response to the CRL planned thereafter. The APOLLO trial is also intended to support potential marketing applications outside the United States.

In its iron homeostasis portfolio, DISC-0974, targeting anemia of myelofibrosis (MF) and inflammatory bowel disease (IBD), is progressing through clinical trials. Initial data from the Phase 2 RALLY-MF trial demonstrated meaningful anemia responses, and topline data is expected in the second half of 2026. A Phase 2 trial in IBD patients was initiated in the first quarter of 2026. DISC-3405, designed to induce hepcidin production, is also in Phase 2 development for polycythemia vera (PV) and Phase 1b for sickle cell disease (SCD), with initial data expected in the second half of 2026. The company also continues to advance its preclinical anti-HJV monoclonal antibody, DISC-0998, for anemia associated with inflammatory diseases.

As of December 31, 2025, Disc Medicine reported cash, cash equivalents, and marketable securities totaling $791.2 million. The company believes these resources will be sufficient to fund operations and debt service obligations into 2029, without accounting for potential revenue from product sales. The company's employee headcount stood at 155, with a focus on expanding its development and regulatory capabilities. The company continues to rely on third-party contract development and manufacturing organizations (CDMOs) for the production of its product candidates.

About Disc Medicine, Inc.

Disc Medicine, Inc. is a biopharmaceutical company focused on developing therapies for hematologic diseases. Its pipeline includes product candidates targeting red blood cell formation, heme biosynthesis, and iron homeostasis. The company leverages validated biological pathways to address conditions like porphyrias, anemia, and polycythemia vera, aiming to improve patient outcomes through innovative, mechanism-based treatments and strategic collaborations.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.